New drug combo targets Gene-Mutant breast cancer in chinese patients
NCT ID NCT04544189
First seen Apr 08, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This study tests whether adding alpelisib to standard fulvestrant therapy can delay cancer growth in Chinese men and postmenopausal women with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that worsened after prior hormone therapy. About 69 participants will receive either the drug combo or a placebo combo. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Hefei, Anhui, 230001, China
-
Novartis Investigative Site
Hefei, Anhui, 230031, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050011, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150081, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450008, China
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Changsha, Hunan, 410013, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210009, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
Nanchang, Jiangxi, 330009, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Shengyang, Liaoning, 110042, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110011, China
-
Novartis Investigative Site
Jinan, Shandong, 250117, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310016, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310022, China
-
Novartis Investigative Site
Beijing, 100021, China
-
Novartis Investigative Site
Bengbu, 233004, China
-
Novartis Investigative Site
Dalian, 116000, China
-
Novartis Investigative Site
Qingdao, 266000, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Tianjin, 300480, China
Conditions
Explore the condition pages connected to this study.